JPRN-UMIN000011990
已完成
未知
Endocrinological profiles in patients with prostate cancer treated with LHRH antagonist - Endocrinological profiles of LHRH antagonist
Department of Urology, Gunma University Graduate School of Medicine0 个研究点目标入组 50 人2013年10月8日
概览
- 阶段
- 未知
- 干预措施
- 未指定
- 疾病 / 适应症
- 未指定
- 发起方
- Department of Urology, Gunma University Graduate School of Medicine
- 入组人数
- 50
- 状态
- 已完成
- 最后更新
- 2年前
概览
简要总结
Degarelix reduced serum testosterone levels soon after the first administration. It also reduced serum adrenal androgen levels.
研究者
入排标准
入选标准
- 未提供
排除标准
- •1\.Patients treated with concomitant anti\-androgens. 2\.Patients treated with concomitant medicines that affect serum sex hormone levels.
结局指标
主要结局
未指定
相似试验
Unknown
2 期
Efficacy Study of Switching to a Lutenizing Hormone-releasing Hormone (LHRH) Antagonist From a LHRH Agonist to Treat Progressive Castrate Resistant Prostate Cancer (CRPC)Prostate NeoplasmNCT01630967British Columbia Cancer Agency40
已完成
不适用
Androgen Deprivation Therapy Prior to Prostatectomy for Patients with Intermediate and High Risk Prostate CancerProstate CancerProstatic AdenocarcinomaNCT01542021Memorial Sloan Kettering Cancer Center41
终止
1 期
Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate CancerProstate CancerProstatic NeoplasmsCastrate-resistant Prostate Cancer (CRPC)Androgen-insensitive Prostate CancerHormone-refractory Prostate CancerMetastatic DiseaseNCT01020305Sandy Srinivas5
已完成
2 期
Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate CancerProstate CancerNCT01491971Ferring Pharmaceuticals76
已完成
不适用
Effect of dutasteride for relieving benign prostatic obstructioBenign Prostatic HyperplasiaJPRN-UMIN000004454Department of Urology, Nagoya University School of Medicine60